Companies Dominating the Oncology Adjuvants Landscape
- Sanofi S.A
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- Bristol Myers Squibb
- Eli Lilly and Company
- Biogen AstraZeneca plc
- Pfizer Inc.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- SL Pharmaceutical
- Sanjiu Medical
- Hisun Pharmaceuticals USA Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of oncology adjuvants is assessed at USD 603.32 million.
The oncology adjuvants market size was over USD 581.57 million in 2024 and is projected to reach USD 1.01 billion by 2037, growing at around 4.4% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of cancer and increasing number of cancer research intitutes will boost the market growth.
North America industry is likely to hold largest revenue share of 35% by 2037, due to rising substantial prevalence of cancer in the region. s
"The major players in the market are Amgen Inc., Bristol Myers Squibb, Eli Lilly and Company, Biogen AstraZeneca plc, Pfizer Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., and others. "
